Lantheus (NASDAQ:LNTH) Price Target Cut to $135.00

Lantheus (NASDAQ:LNTH) had its price objective decreased by Truist Financial from $141.00 to $135.00 in a research report report published on Thursday morning, Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

LNTH has been the topic of several other research reports. StockNews.com lowered shares of Lantheus from a buy rating to a hold rating in a research report on Friday, May 3rd. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a buy rating in a research report on Thursday, July 25th. SVB Leerink lifted their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an outperform rating in a research report on Thursday, July 11th. JMP Securities lifted their price target on shares of Lantheus from $100.00 to $130.00 and gave the company an outperform rating in a research report on Wednesday, July 10th. Finally, Mizuho lifted their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Lantheus presently has an average rating of Moderate Buy and an average target price of $119.00.

Lantheus Trading Down 7.0 %

LNTH opened at $90.75 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.55. The company’s 50 day simple moving average is $92.18 and its two-hundred day simple moving average is $73.37. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a market capitalization of $6.30 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period last year, the business earned $1.40 earnings per share. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. Analysts expect that Lantheus will post 6.46 EPS for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the sale, the director now directly owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,799 shares of company stock worth $3,769,262. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently modified their holdings of LNTH. GAMMA Investing LLC lifted its position in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 247 shares during the period. Principal Securities Inc. acquired a new position in Lantheus during the fourth quarter worth about $28,000. Fidelis Capital Partners LLC acquired a new position in Lantheus during the first quarter worth about $34,000. Finally, FinTrust Capital Advisors LLC grew its position in Lantheus by 53.6% during the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 232 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.